Navigation Links
Novel compound may lessen heart attack damage
Date:2/7/2008

DURHAM, NC A novel drug designed to lessen muscle damage from a heart attack has passed initial safety tests at the Duke Clinical Research Institute. Results of the study, available online and to be published in the February 19 issue of the journal Circulation, reflect the first time the drug has been tested in humans.

The drug, known as KAI-9803, blocks the activity of an enzyme called delta protein kinase C that triggers cell and tissue death in the aftermath of percutaneous coronary intervention, or PCI. PCI is a set of procedures including balloon angioplasty and stent placement that clear and prop open clogged coronary blood vessels that lead to a heart attack a process known as reperfusion.

Although the trial (known as DELTA-MI) was not designed to demonstrate the efficacy of KAI-9803, researchers say early data suggest it appears to be a promising compound.

Weve needed something like this for a long time, says Dr. Matthew Roe, a cardiologist at Duke and the lead investigator of the trial.

Roe says many people may not realize that the heart suffers damage at two major points in a heart attack: first, when a blockage in a coronary artery prevents blood and oxygen from getting to the heart, and then again when the patient undergoes PCI and normal blood flow is restored through reperfusion.

We may not be able to intervene in the first stage of a heart attack, but we think there may be ways to limit damage caused by reperfusion injury, he says.

Researchers randomized 154 patients who had suffered heart attacks and were eligible for PCI into either one of four dosing levels of KAI-9803 or a placebo. Patients underwent PCI with physicians injecting the drug directly into their coronary blood vessels during the procedure.

The goal of the treatment is to flood the heart damaged by the heart attack with the drug immediately before blood flow is restored and then again, immediately afterwards, says Roe. We believe that bathing the area with this novel compound may block the damaging cascade of events that are triggered specifically by delta protein kinase C when blood is restored to the heart muscle, he says.

Earlier studies in animals showed that KAI-9803 lessened damage to the heart muscle and quickly restored its pumping function.

We designed the DELTA MI trial to find out if KAI-9803 is safe for humans, and we accomplished that goal; we did not see any serious side effects, says Roe. We also found, however, many promising signs of beneficial drug activity such as lessened damage to the heart muscle and improvement in electrical conductivity in the heart that corresponded to restoration of blood flow to the heart muscle. As a result, we feel this drug has the potential to be helpful in reducing the impact of a heart attack in humans.


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Novel molecules developed at UB can boost vaccine potency
2. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
3. Novel vaccine concept developed by scientists at the Wistar Institute
4. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
5. Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology
6. Statement by AARP CEO Bill Novelli on President Bushs State of the Union
7. New method enables design, production of extremely novel drugs
8. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
9. Speedy Procedures Demonstrate Excitement and Continued Interest in Novel Multi-Electrode Ablation System
10. Novel anticancer strategy moves from laboratory to clinic
11. FDA approves Bystolic, a novel beta blocker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2019)... ... ... AutismOne has announced that Dr. Andrew Wakefield, an author and award-winning filmmaker, ... at the AutismOne 2019 Conference will address what herd immunity is and what it ... examine the consequences - real and potential - for vaccines that do not reproduce ...
(Date:3/20/2019)... ... March 20, 2019 , ... Adam Equipment, a leading provider ... at Forum Labo Paris from 26-28 March at Paris expo Porte de Versailles in ... the Solis series of balances. Both balance lines include models that deliver ...
(Date:3/20/2019)... ... March 20, 2019 , ... Caring.com, the nation’s most visited website for ... for 2019. The medical alert provider was recognized as the Best Standalone Mobile ... the list based on its demonstration of excellent customer service, transparency and affordability. With ...
(Date:3/19/2019)... ... 19, 2019 , ... Adult superstar, sex educator and exclusive Wicked Pictures contract ... Sex: Senior Sex’ will begin production on April 17 in Los Angeles. , Media ... of “Guide to Wicked Sex” brings together jessica drake with senior sex expert Joan ...
(Date:3/19/2019)... PHILADELPHIA (PRWEB) , ... March 19, 2019 , ... ... oil, recently conducted a survey that studied the attitudes surrounding cannabis and its ... The study considered questions regarding changing attitudes about marijuana given recent ...
Breaking Medicine News(10 mins):
(Date:3/20/2019)... Ind. (PRWEB) , ... March 20, 2019 , ... ... Group of companies. A leading third-party retirement plan administration firm specializing in quality ... plans. , As CEO Brad Lankford said, “Latitude is as much an idea ...
(Date:3/20/2019)... ... March 20, 2019 , ... ... announced today that it has partnered with ZRx Outcomes Research Inc. to ... research, systematic literature review, comparative effectiveness research (CER), decision modeling, dossier development ...
(Date:3/19/2019)... ... 19, 2019 , ... AltaPointe Health is taking part in ... Independent for Life (SAIL). At the core of the SAIL program is the ... stay active and reduce their chances of falling. , Twenty-three AltaPointe staff ...
Breaking Medicine Technology: